Ants could be the next line of defense against cancer.
A study published in the journal Proceedings of Royal Society B: Biological Sciences focused on Ants and their keen sense of smell. Ants use smell via their thin sensory appendages that sit on top of their heads to do almost everything, including hunt for food, spotting mates, and protecting their young.
In the study, scientists used pieces of a breast cancer tumor, which were grafted onto mice, and then trained 35 ants to associate urine from the infected mice with sugar. In analyzing, scientists detected that the ants would hover for longer periods of time near the sick mouse rather than the healthy one.
Using ants to detect cancers would be a cost-cutting tool. Currently, cancers are diagnosed by blood withdrawal, biopsies, and colonoscopies, which are all considered invasive as well as being expensive procedures. Utilizing ants to screen for cancer would be significantly more reasonable.
While dogs have similar capabilities in that they are able to detect cancer in humans through smell, they take much longer to train. Baptiste Piqueret, a postdoctoral fellow at the Max Planck Institute for Chemical Ecology in Germany, said ants would be the ideal animal to use because they have good memories, are easy to train and don't bite.
Though progress has been made with ants and their cancer detection capabilities, there is still more research to be done on their efficacy. The next phase of the study will be human trials to see if ants are able to sniff out cancers through human excrement.
An FDA panel has recommended the low-dose Pfizer vaccine for kids ages five to 11. The recommendation now cues up the FDA to authorize the vaccine. Next week, the CDC will consider its own authorization. Once signed off by the CDC, the Pfizer vaccine can be administered in children immediately. Dr. Christina Johns, Senior Medical Advisor at PM Pediatrics, joined Cheddar's Search for a Cure.
Dr. Vivek Cherin, Internal Medicine Physician at Amita Health, joined Cheddar's Search for a Cure to break down what we need to know about eligibility and availability of COVID-19 vaccine boosters.
World leaders will converge this weekend at the 2021 G20 Summit in Rome and the UN COP26 conference in Glasgow with the climate crisis on the agenda. Lord Adair Turner, chair of the Energy Transitions Commission, joined Cheddar to discuss what people can expect to come out of the climate-focused conferences. Turner also noted that one of the biggest hurdles for the attending nations will be coming to a uniform decision on expanding on the Paris Climate Accord goals that have become insufficient to prevent global warming by 1.5 degrees celsius.
Nicole Lambert, President at Myriad Genetics joins ChedHER to discuss how to expand access to genetic testing for all women, and how her experience as a 'pre-vivor' motivates her role in the industry.
Carlo and Baker cover Facebook's big rebrand, the latest on Biden's economic agenda and more. Plus, ranking the best Halloween candy and the worst couple's costumes.
Proptech startup Juno recently raised $20 million in a Series A funding round. The company says the funds will be used to further its mission of building sustainable and affordable apartment buildings across the United States. Juno Co-Founder and CEO Jonathan Sherr joined Cheddar News' Closing Bell to discuss.
Stacey Stevens, President of iCAD, joins 'Cheddar Innovates' to discuss how 'Profound A.I. Risk' works as a short-term breast cancer risk estimation for women.
On this episode of 'Cheddar Innovates': President of iCAD breaks down how its technology is being used as a short-term breast cancer risk estimation for women; A look at Curiosity Stream's 'The Science of Thrills.'
Pharmaceutical company Merck has announced that it will share the formula of its COVID-19 pill with poor countries free of charge. The company still intends to charge wealthier nations leaving the end cost at more than $700 per five-day treatment course.
Dems race for a deal on President Biden's economic agenda ahead of his big foreign trip. What to make of the latest threat assessment in Afghanistan. Plus, the meme cryptocurrency of the moment that's now worth more than many Fortune 500 companies.
